BR112012002064A2 - método para determinar se ec145 é indicado para o tratamento de um paciente com um tumor ovariano ou um tumor de pulmão; método para prever uma resposta de um tumor ovariano ou um tumor de pulmão de um paciente a terapia com ec145; método de tratamento de câncer ovariano resistente à platina em um paciente necessitando dele; uso de ec145 em combinação com doxorrubicina lipossômica peguilada; uso de ec145 para a fabricação de um medicamento; método para obter um benefício clínico comparado a tratamento com uma quantidade terapêutica de doxorrubicina lipossômica peguilada no tratamento de câncer ovariano resistente à platina em um paciente necessitando dele; método para selecionar um paciente para tratamento; composição farmacêutica; unidade de dosagem, método para determinar se um paciente com um tumor tem receptores de folato funcionalmente ativos presentes no tumor do paciente; método de tratamento de um tumor epitelial expressando receptor de folato em um paciente necessitando dele; e; método para obter um benefício clínico no tratamento de um tumor epitelial expressando receptor de folato em um paciente necessitando dele - Google Patents

método para determinar se ec145 é indicado para o tratamento de um paciente com um tumor ovariano ou um tumor de pulmão; método para prever uma resposta de um tumor ovariano ou um tumor de pulmão de um paciente a terapia com ec145; método de tratamento de câncer ovariano resistente à platina em um paciente necessitando dele; uso de ec145 em combinação com doxorrubicina lipossômica peguilada; uso de ec145 para a fabricação de um medicamento; método para obter um benefício clínico comparado a tratamento com uma quantidade terapêutica de doxorrubicina lipossômica peguilada no tratamento de câncer ovariano resistente à platina em um paciente necessitando dele; método para selecionar um paciente para tratamento; composição farmacêutica; unidade de dosagem, método para determinar se um paciente com um tumor tem receptores de folato funcionalmente ativos presentes no tumor do paciente; método de tratamento de um tumor epitelial expressando receptor de folato em um paciente necessitando dele; e; método para obter um benefício clínico no tratamento de um tumor epitelial expressando receptor de folato em um paciente necessitando dele

Info

Publication number
BR112012002064A2
BR112012002064A2 BR112012002064A BR112012002064A BR112012002064A2 BR 112012002064 A2 BR112012002064 A2 BR 112012002064A2 BR 112012002064 A BR112012002064 A BR 112012002064A BR 112012002064 A BR112012002064 A BR 112012002064A BR 112012002064 A2 BR112012002064 A2 BR 112012002064A2
Authority
BR
Brazil
Prior art keywords
patient
tumor
treatment
need
obtaining
Prior art date
Application number
BR112012002064A
Other languages
English (en)
Portuguese (pt)
Inventor
Paul Leamon Christopher
Morgenstern David
Messmann Richard
Original Assignee
Endocyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endocyte Inc filed Critical Endocyte Inc
Publication of BR112012002064A2 publication Critical patent/BR112012002064A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112012002064A 2009-07-31 2010-07-30 método para determinar se ec145 é indicado para o tratamento de um paciente com um tumor ovariano ou um tumor de pulmão; método para prever uma resposta de um tumor ovariano ou um tumor de pulmão de um paciente a terapia com ec145; método de tratamento de câncer ovariano resistente à platina em um paciente necessitando dele; uso de ec145 em combinação com doxorrubicina lipossômica peguilada; uso de ec145 para a fabricação de um medicamento; método para obter um benefício clínico comparado a tratamento com uma quantidade terapêutica de doxorrubicina lipossômica peguilada no tratamento de câncer ovariano resistente à platina em um paciente necessitando dele; método para selecionar um paciente para tratamento; composição farmacêutica; unidade de dosagem, método para determinar se um paciente com um tumor tem receptores de folato funcionalmente ativos presentes no tumor do paciente; método de tratamento de um tumor epitelial expressando receptor de folato em um paciente necessitando dele; e; método para obter um benefício clínico no tratamento de um tumor epitelial expressando receptor de folato em um paciente necessitando dele BR112012002064A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23059509P 2009-07-31 2009-07-31
US34644410P 2010-05-19 2010-05-19
US35102210P 2010-06-03 2010-06-03
PCT/US2010/043992 WO2011014821A1 (en) 2009-07-31 2010-07-30 Folate-targeted diagnostics and treatment

Publications (1)

Publication Number Publication Date
BR112012002064A2 true BR112012002064A2 (pt) 2017-05-09

Family

ID=43529728

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012002064A BR112012002064A2 (pt) 2009-07-31 2010-07-30 método para determinar se ec145 é indicado para o tratamento de um paciente com um tumor ovariano ou um tumor de pulmão; método para prever uma resposta de um tumor ovariano ou um tumor de pulmão de um paciente a terapia com ec145; método de tratamento de câncer ovariano resistente à platina em um paciente necessitando dele; uso de ec145 em combinação com doxorrubicina lipossômica peguilada; uso de ec145 para a fabricação de um medicamento; método para obter um benefício clínico comparado a tratamento com uma quantidade terapêutica de doxorrubicina lipossômica peguilada no tratamento de câncer ovariano resistente à platina em um paciente necessitando dele; método para selecionar um paciente para tratamento; composição farmacêutica; unidade de dosagem, método para determinar se um paciente com um tumor tem receptores de folato funcionalmente ativos presentes no tumor do paciente; método de tratamento de um tumor epitelial expressando receptor de folato em um paciente necessitando dele; e; método para obter um benefício clínico no tratamento de um tumor epitelial expressando receptor de folato em um paciente necessitando dele

Country Status (13)

Country Link
US (2) US20120128587A1 (https=)
EP (1) EP2460013A4 (https=)
JP (1) JP2013501224A (https=)
KR (1) KR20120050462A (https=)
CN (2) CN104857534A (https=)
AU (1) AU2010278734A1 (https=)
BR (1) BR112012002064A2 (https=)
CA (1) CA2769754A1 (https=)
IL (1) IL217744A0 (https=)
IN (1) IN2012DN01708A (https=)
NZ (1) NZ598145A (https=)
RU (1) RU2012105641A (https=)
WO (1) WO2011014821A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4464384A3 (en) 2007-08-17 2025-01-08 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
KR20130140033A (ko) 2010-11-12 2013-12-23 엔도사이트, 인코포레이티드 암을 치료하는 방법들
KR20140022879A (ko) * 2011-04-12 2014-02-25 엔도사이트, 인코포레이티드 고체 약학 조성물
BR112015011118B1 (pt) 2012-11-15 2022-12-13 Endocyte, Inc Conjugado; composição farmacêutica; e uso de um conjugado
US20140154702A1 (en) * 2012-11-30 2014-06-05 Endocyte, Inc. Methods For Treating Cancer Using Combination Therapies
US10188738B2 (en) 2013-10-16 2019-01-29 Université Libre de Bruxelles Formulations useful in the treatment of proliferative diseases affecting the respiratory tract
LT4095130T (lt) 2013-10-18 2024-04-25 Novartis Ag Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti
BR112016010927A2 (pt) 2013-11-14 2017-08-08 Endocyte Inc Conjugado de fórmula
WO2015077303A1 (en) 2013-11-19 2015-05-28 Purdue Research Foundation Patient selection method for inflammation
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
CA2973380A1 (en) * 2015-01-11 2016-07-14 Endocyte, Inc. Cancer imaging agent
IL237525A (en) 2015-03-03 2017-05-29 Shalom Eli Method for labeling a prostate-specific membrane antigen with a radioactive isotope
WO2018182776A1 (en) * 2016-03-29 2018-10-04 Endocyte, Inc. Folate conjugate for use in targeting tumor associated macrophages
WO2017192863A1 (en) 2016-05-04 2017-11-09 L.E.A.F. Holdings Group Llc Targeted liposomal gemcitabine compositions and methods thereof
WO2017205661A1 (en) * 2016-05-25 2017-11-30 Purdue Research Foundation Method of treating cancer by targeting myeloid-derived suppressor cells
US12208102B2 (en) 2018-04-17 2025-01-28 Endocyte, Inc. Methods of treating cancer
CN114096264B (zh) 2019-05-20 2025-03-14 因多塞特股份有限公司 制备psma缀合物的方法
CN121337736A (zh) * 2025-12-16 2026-01-16 临沂市人民医院 多柔比星与免疫调节剂共载脂质体的制备及其协同抗肿瘤用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1592457T3 (da) * 2003-01-27 2012-10-22 Endocyte Inc Folat-vinblastin-konjugat som lægemiddel
ATE494012T1 (de) * 2004-12-21 2011-01-15 Nektar Therapeutics Stabilisierte polymer-thiol-reagenzien
RU2007128036A (ru) * 2004-12-23 2009-01-27 Пердью Рисерч Фаундейшн (Us) Способ получения изображения позитронно-эмиссионной томографией
EP1863816B1 (en) * 2005-03-16 2014-06-25 Endocyte, Inc. Synthesis and purification of pteroic acid and conjugates thereof
ATE460668T1 (de) * 2005-03-30 2010-03-15 Purdue Research Foundation Verfahren zur prognose von brustkrebs mittels quantifizierung von zellulären folat vitamin rezeptoren
JP2006316040A (ja) * 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
US20100112039A1 (en) * 2006-10-25 2010-05-06 Schering Corporation Methods of treating ovarian cancer
BRPI0812970A2 (pt) * 2007-06-25 2019-09-24 Endocyte Inc conjugados contendo espaçadores hidrofílicos

Also Published As

Publication number Publication date
US20140140925A1 (en) 2014-05-22
EP2460013A1 (en) 2012-06-06
IN2012DN01708A (https=) 2015-06-05
US20120128587A1 (en) 2012-05-24
JP2013501224A (ja) 2013-01-10
WO2011014821A1 (en) 2011-02-03
KR20120050462A (ko) 2012-05-18
CN102549434A (zh) 2012-07-04
EP2460013A4 (en) 2013-04-03
CN104857534A (zh) 2015-08-26
CA2769754A1 (en) 2011-02-03
RU2012105641A (ru) 2013-09-10
NZ598145A (en) 2014-10-31
IL217744A0 (en) 2012-03-29
AU2010278734A1 (en) 2012-02-23

Similar Documents

Publication Publication Date Title
BR112012002064A2 (pt) método para determinar se ec145 é indicado para o tratamento de um paciente com um tumor ovariano ou um tumor de pulmão; método para prever uma resposta de um tumor ovariano ou um tumor de pulmão de um paciente a terapia com ec145; método de tratamento de câncer ovariano resistente à platina em um paciente necessitando dele; uso de ec145 em combinação com doxorrubicina lipossômica peguilada; uso de ec145 para a fabricação de um medicamento; método para obter um benefício clínico comparado a tratamento com uma quantidade terapêutica de doxorrubicina lipossômica peguilada no tratamento de câncer ovariano resistente à platina em um paciente necessitando dele; método para selecionar um paciente para tratamento; composição farmacêutica; unidade de dosagem, método para determinar se um paciente com um tumor tem receptores de folato funcionalmente ativos presentes no tumor do paciente; método de tratamento de um tumor epitelial expressando receptor de folato em um paciente necessitando dele; e; método para obter um benefício clínico no tratamento de um tumor epitelial expressando receptor de folato em um paciente necessitando dele
Bernier et al. Molecular therapy in head and neck oncology
Lin et al. Targeting protease activated receptor-1 with P1pal-12 limits bleomycin-induced pulmonary fibrosis
Freeman et al. Effect of perioperative lidocaine and cisplatin on metastasis in a murine model of breast cancer surgery
Li et al. Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade®) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC)
Poyurovsky et al. The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study
Buhl et al. Comparable efficacy of ciclesonide once daily versus fluticasone propionate twice daily in asthma
KR20230107568A (ko) 섬유증 치료 방법
Zhao et al. Morusin enhances the antitumor activity of MAPK pathway inhibitors in BRAF-mutant melanoma by inhibiting the feedback activation of STAT3
Nie et al. Synergistic interaction between dexmedetomidine and ulinastatin against vincristine-induced neuropathic pain in rats
Li et al. Ginsenoside (20S)-protopanaxatriol induces non-protective autophagy and apoptosis by inhibiting Akt/mTOR signaling pathway in triple-negative breast cancer cells
San Martín et al. Sonidegib in the treatment of locally advanced basal cell carcinoma
Zhong et al. Mechanisms, assessment, and exercise interventions for skeletal muscle dysfunction post-chemotherapy in breast cancer: from inflammation factors to clinical practice
Liu et al. AS-IV enhances the antitumor effects of propofol in NSCLC cells by inhibiting autophagy
Belyaeva et al. Application of laser phoresis in complicated postmenopausal osteoporosis
Sharma et al. Alveolar macrophage activation in obese patients with obstructive sleep apnea
WO2019100003A1 (en) Combination therapy targeting cancer associated with the hedgehog pathway
BRPI1009003A2 (pt) "método para expressão recombinante de um ccn1 humano, uso de um ccn1 humano, anticorpo contra ccn1 humano, uso de um anticorpo contra ccn1 humano, método para a fabricação de um medicamento para o tratamento de doenças e composição farmacêutica"
Gervais et al. Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer
Rahal et al. Implications and efficacy of aromatase inhibitors in combination and monotherapy for the treatment of lung cancer
Lee et al. A pilot study for the early assessment of the effects of BMS-754807 plus gefitinib in an H292 tumor model by [18F] fluorothymidine-positron emission tomography
Bebb et al. Don’t jump to rash conclusions
Vivo Protective Effect of Atazanavir Sulphate Against Pulmonary
EA200801854A1 (ru) Новые композиции
Butt Overcoming resistance: Targeting the PI3K/mTOR pathway in endocrine refractory breast cancer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]